BioPharma: Expert Call: Neurologist on ADA/ADP Treatment Landscape - Today, July 23

Research evidence excerpt

BioPharma: Expert Call: Neurologist on ADA/ADP Treatment Landscape - Today, July 23

Deutsche Bank

Research

North America Industry Date

Pharmaceuticals BioPharma 23 July 2026

Expert Call: Neurologist on ADA/ADP

David Hoang, M.D., Ph.D. Treatment Landscape - Today, July 23

Research Analyst

+1-212-250-1184

KOL Perspective on ADA/ADP Treatment Landscape

Please join us today, July 23, at 1:00pm ET for an expert call with Dr. William Sam Beck

Mantyh, behavioral and cognitive neurologist, Associate Professor, and Clinical Research Associate

+1-929-354-4311 Director of the Behavior and Memory Clinic at the University of Minnesota

Medical School. Rosemary Li

Research Associate

In the coming years, the Alzheimer's disease (AD) landscape is set to undergo a +1-347-985-6026

significant evolution. While recent breakthroughs with disease-modifying

therapies like BIIB’s Leqembi and LLY’s Kisunla have captured the spotlight by Samuel Ravina

targeting the underlying amyloid pathology, and several pipeline drugs are now Research Associate

+1-917-244-0223

being developed that target tau, a new focus on addressing the accompanying

neuropsychiatric symptoms of the disease is rapidly emerging. The markets for

Alzheimer's disease agitation (ADA) and psychosis (ADP) are shifting from a

paradigm dominated by the off-label use of antidepressants and antipsychotics

to a more defined, branded therapeutic space. Although HLUN’s Rexulti was the

first to secure an ADA-specific label, its associated safety concerns (including a

class boxed warning for increased mortality in elderly patients with dementia-

related psychosis shared by other antipsychotics) have left a significant unmet

need. The recent approval and launch of AXSM’s Auvelity for ADA (previously